What is the history of 22q11 DiGeorge Syndrome?

TL;DR: 22q11 DiGeorge Syndrome was first described by pediatrician Angelo DiGeorge in 1965 as a triad of absent thymus, hypoparathyroidism, and cardiac anomalies. Our understanding has evolved from viewing it as a group of separate conditions to recognizing it as a unified genetic disorder caused by a microdeletion on chromosome 22, which now allows for earlier, more precise diagnosis and multidisciplinary care.

How was 22q11 DiGeorge Syndrome first identified?

The medical history of 22q11 DiGeorge Syndrome began in 1965 when Dr. Angelo DiGeorge presented his findings at a meeting of the American Pediatric Society. He identified a cluster of infants born with absent or underdeveloped thymus and parathyroid glands, which led to immune deficiencies and severe hypocalcemia. During the same era, other researchers, such as Shprintzen, described overlapping clinical features—including specific facial characteristics and palatal abnormalities—under names like Velocardiofacial Syndrome. For many years, these were treated as distinct, unrelated diagnoses, causing confusion for families who were often given different labels for the same underlying 22q11 DiGeorge Syndrome condition.

How has our genetic understanding of the condition changed?

The landscape of 22q11 DiGeorge Syndrome shifted dramatically in the early 1980s and 1990s. Advances in molecular cytogenetics, specifically the development of Fluorescence In Situ Hybridization (FISH) and later Chromosomal Microarray (CMA), allowed scientists to identify a consistent microdeletion on the long arm of chromosome 22 (22q11.2). This discovery was a "Eureka" moment for medicine, as it linked the disparate symptoms previously described by DiGeorge, Shprintzen, and others into a single clinical entity. This unified genetic understanding significantly improved the diagnostic process, moving away from clinical guesswork toward definitive molecular confirmation.

What are the major milestones in the history of clinical management?

The evolution of care for 22q11 DiGeorge Syndrome reflects the transition from reactive to proactive, multidisciplinary management. Historical milestones include:

• 1960s-70s: Initial focus was on acute stabilization of hypocalcemia and management of neonatal cardiac defects.


• 1980s: Introduction of thymic transplantation and improved surgical techniques for congenital heart disease increased survival rates.


• 1990s: Recognition of the neurodevelopmental and psychiatric aspects of 22q11 DiGeorge Syndrome led to earlier speech therapy and psychiatric support.


• 2000s-Present: Implementation of comprehensive, "whole-person" care models involving immunologists, cardiologists, endocrinologists, and genetic counselors.

How has patient advocacy shaped the modern experience?

Historically, the fragmentation of the diagnosis meant that patients with 22q11 DiGeorge Syndrome were often isolated, as they were scattered across different medical specialties. The rise of global patient advocacy groups has been transformative. Today, the DiseaseMaps.org community, which includes 215 members living with 22q11 DiGeorge Syndrome, serves as a vital hub for sharing lived experiences. These advocacy efforts have shifted the narrative from a focus solely on morbidity to a focus on quality of life, neurodiversity, and improved transition-to-adult-care programs.

Next steps

• Consult with a clinical geneticist to review updated testing options and family recurrence risks.


• Connect with the 215 members on DiseaseMaps.org to share resources and find local specialists.


• Visit the International 22q11.2 Foundation for the latest clinical guidelines and educational materials.


• Maintain a consolidated "health passport" that summarizes your specific 22q11 DiGeorge Syndrome history for use across different medical departments.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: 22q11.2 deletion syndrome.


• Orphanet: 22q11.2 deletion syndrome (ORPHA:96156).


• OMIM (Online Mendelian Inheritance in Man): 22q11.2 Deletion Syndrome (Entry #188400).


• The International 22q11.2 Foundation.